Patients receiving a NSAID (non-selective non-steroidal anti-inflammatory drug) as well as a PPI (proton pump inhibitor) - to treat inflammation and pain in arthritis - are more than four times more likely to suffer upper or lower gastrointestinal adverse clinical outcomes compared to those receiving a cyclo-oxygenase (COX)-2 selective NSAID.
The findings of the CONDOR study, reported in an Article Online First in the medical journal The Lancet, should encourage review of approaches to reduce risk of NSAID treatment. The study is written by Professor Francis K L Chan, Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong Special Administrative Region, China, and Professor Jay Goldstein, University of Illinois at Chicago, IL, USA, and colleagues. The study is being presented at the European League Against Rheumatism (EULAR) Annual Conference in Rome.
Copyright ArthritisInsight.com